Proton

Aligos Therapeutics Announces First Subjects Dosed in the Phase 2a HERALD Study of ALG-055009 in MASH Subjects

Retrieved on: 
Wednesday, April 3, 2024
Proton, Magnetic resonance imaging, SAN, Biomarker, MASH, MBA, Doctor of Philosophy, Therapy, Safety, Liver, Magnetic resonance, Pharmaceutical industry

SOUTH SAN FRANCISCO, Calif., April 03, 2024 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS, “Aligos”), a clinical stage biopharmaceutical company focused on developing novel therapeutics to address unmet medical needs in liver and viral diseases, today announced that dosing in the Phase 2a HERALD study of ALG-055009 has been initiated in subjects with metabolic dysfunction-associated steatohepatitis (MASH).

Key Points: 
  • SOUTH SAN FRANCISCO, Calif., April 03, 2024 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS, “Aligos”), a clinical stage biopharmaceutical company focused on developing novel therapeutics to address unmet medical needs in liver and viral diseases, today announced that dosing in the Phase 2a HERALD study of ALG-055009 has been initiated in subjects with metabolic dysfunction-associated steatohepatitis (MASH).
  • “Dosing the first subjects in our Phase 2a HERALD study is an important milestone for Aligos,” said Lawrence Blatt, Ph.D., MBA, Chairman, President, and Chief Executive Officer at Aligos Therapeutics.
  • “We are pleased by the engagement of the clinicians and subjects, demonstrating the need for additional oral MASH therapies.
  • Topline safety and efficacy data from this study are expected in Q4 2024.

American Shared Hospital Services Reports Fourth Quarter 2023 Financial Results

Retrieved on: 
Wednesday, March 27, 2024
Proton, Growth, Three Months, Radiosurgery, Proton therapy, The Twelve Months, Partnership, Webcast, Patient, Sale, Cancer, Software, Overalls, Orlando Health, AMS, Marketing, Cobalt, Video game

Adjusted EBITDA, a non-GAAP financial measure, was $2,679,000 for the fourth quarter of 2023, compared to $2,161,000 for the fourth quarter of 2022.

Key Points: 
  • Adjusted EBITDA, a non-GAAP financial measure, was $2,679,000 for the fourth quarter of 2023, compared to $2,161,000 for the fourth quarter of 2022.
  • Ray Stachowiak, Executive Chairman of American Shared Hospital Services, commented, “2023 was a good year for AMS with continual improvement each quarter.
  • Net income attributable to American Shared Hospital Services in the fourth quarter of 2023 was $415,000, or $0.06 per diluted share, compared to net income of $246,000, or $0.04 per diluted share, for the fourth quarter of 2022.
  • Adjusted EBITDA, a non-GAAP financial measure, was $2,679,000 for the fourth quarter of 2023, compared to $2,161,000 for the fourth quarter of 2022.

RocketStar Announces Successful Demonstration of Fusion-Enhanced Pulsed Plasma Electric Propulsion

Retrieved on: 
Wednesday, March 20, 2024
Nuclear fusion, Radiation, USSF, Plasma, Georgia Tech, Boron, Proton, SBIR, University, Spacecraft, OTV, Carbon, AFWERX, Nuclear engineering, Alpha, Firestar, Gamma, SpaceX, ION Satellite Carrier, Lithium

NEW YORK, March 20, 2024 (GLOBE NEWSWIRE) -- RocketStar Inc. has successfully demonstrated the FireStar Drive, a groundbreaking electric propulsion unit for spacecraft that uses nuclear fusion-enhanced pulsed plasma.

Key Points: 
  • NEW YORK, March 20, 2024 (GLOBE NEWSWIRE) -- RocketStar Inc. has successfully demonstrated the FireStar Drive, a groundbreaking electric propulsion unit for spacecraft that uses nuclear fusion-enhanced pulsed plasma.
  • This innovative device significantly boosts the performance of RocketStar's base water-fueled pulsed plasma thruster by utilizing a unique form of aneutronic nuclear fusion.
  • The fusion discovery was first made during an SBIR Phase 1 for AFWERX where boronated water was introduced into the pulsed plasma thruster’s exhaust plume.
  • “We are very excited to test FireStar for RocketStar,” said Brent Abbott, CRO at Rogue Space Systems.

Aligos Therapeutics Announces the Initiation of the Phase 2a HERALD Study of ALG-055009 in MASH Subjects

Retrieved on: 
Monday, March 18, 2024
Proton, Magnetic resonance imaging, Patient, Biomarker, MASH, Trial of the century, MBA, Doctor of Philosophy, Principal investigator, Therapy, Safety, Pharmacokinetics, Liver, Magnetic resonance, Pharmaceutical industry

SOUTH SAN FRANCISCO, Calif., March 18, 2024 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS, “Aligos”), a clinical stage biopharmaceutical company focused on developing novel therapeutics to address unmet medical needs in liver and viral diseases, today announced the initiation of the Phase 2a HERALD study of ALG-055009 in subjects with metabolic dysfunction-associated steatohepatitis (MASH). Screening of subjects has begun at clinical study sites across the U.S.

Key Points: 
  • The Phase 2a study is being led by Principal Investigator, Dr. Stephen Harrison
    SOUTH SAN FRANCISCO, Calif., March 18, 2024 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS, “Aligos”), a clinical stage biopharmaceutical company focused on developing novel therapeutics to address unmet medical needs in liver and viral diseases, today announced the initiation of the Phase 2a HERALD study of ALG-055009 in subjects with metabolic dysfunction-associated steatohepatitis (MASH).
  • Screening of subjects has begun at clinical study sites across the U.S.
    “ALG-055009 has enhanced potency, greater beta selectivity, and a favorable PK profile.
  • We believe that these optimized pharmacologic properties may result in improved therapeutic outcomes for patients living with MASH.
  • The initiation of the HERALD study is an important next step in achieving our goal to create a best-in-class thyroid hormone receptor beta agonist,” stated Lawrence Blatt, Ph.D., MBA, Chairman, President, and CEO of Aligos Therapeutics.

Advent Technologies Signs Strategic Joint Development Agreement with Siemens Energy to Expedite the Decarbonization of the Maritime Sector

Retrieved on: 
Thursday, April 4, 2024
Technology, Manufacturing, Maritime, Other Energy, Transport, Recycling, Alternative Energy, Environment, Energy, Engineering, Hardware, Proton, Hydrogen, Electricity, Temperature, Advent, Joint, Methanol, Digital, Sanlorenzo S.p.a., Humidity, Ion, Research, Siemens Energy, JDA, CO2, MEA, German, Renewable energy

Advent Technologies Holdings, Inc., an innovation-driven leader in the fuel cell and hydrogen technology sectors, is pleased to announce that its wholly owned subsidiary, Advent Technologies A/S (“Advent”), has signed a Joint Development Agreement (“JDA”) with Siemens Energy, one of the world's leading energy technology companies.

Key Points: 
  • Advent Technologies Holdings, Inc., an innovation-driven leader in the fuel cell and hydrogen technology sectors, is pleased to announce that its wholly owned subsidiary, Advent Technologies A/S (“Advent”), has signed a Joint Development Agreement (“JDA”) with Siemens Energy, one of the world's leading energy technology companies.
  • The innovative clean energy solution resulting from this multi-year collaboration is expected to initially address the power needs of large yachts.
  • This agreement builds upon the strong collaboration between Advent and Siemens Energy, which began in February 2022 with the Sanlorenzo Life Ocean pilot project.
  • Advent Technologies' HT-PEM fuel cells utilizing the innovative Ion Pair™ MEA technology, offer high-temperature operation between 80°C and 240°C.

Chemours and Partners Selected for $60M in U.S. Department of Energy Grants to Support Continued Advancement of Global Hydrogen Economy

Retrieved on: 
Wednesday, March 20, 2024
Other Energy, Utilities, Oil, Gas, Alternative Energy, Energy, General Automotive, Automotive, Other Manufacturing, Engineering, Chemicals, Plastics, Automotive Manufacturing, Manufacturing, Proton, Hydrogen, Chemours, Membrane, CC, Recycling, Electrolysis, PEM, Chemistry, Heart, Roadmap, DOE, Lithium

These selections validate Chemours’ leadership and expertise as a responsible manufacturer of high-quality, durable ionomers and membranes.

Key Points: 
  • These selections validate Chemours’ leadership and expertise as a responsible manufacturer of high-quality, durable ionomers and membranes.
  • The project’s goals include creating products that can be manufactured cost-effectively at scale, a significant challenge the hydrogen industry faces today.
  • “Chemours is committed to using the power of its chemistry to advance the clean energy transition and hydrogen economy.
  • “At Chemours, our advanced chemistry and technology are at the heart of the hydrogen economy and essential to producing and deploying clean hydrogen,” said Gerardo Familiar, President of Advanced Performance Materials at Chemours.

New Proton Therapy Treatment Centre named in Ben Stelter’s honour announced

Retrieved on: 
Thursday, March 14, 2024
Other Philanthropy, Oncology, Health, Children, Family, Philanthropy, Consumer, Foundation, Proton, University, Proton therapy, Intelligence, Physician, Patient, Neoplasm, Research, Travel, Cancer, MD, Surgeon, Ecosystem, Machine learning, Multimedia, Radiation therapy, Edmonton Oilers, Oiler, Medical imaging

Today, WestCan Proton Therapy Inc. announced their plans to invest in Canada’s first proton therapy treatment centre to be built in Edmonton.

Key Points: 
  • Today, WestCan Proton Therapy Inc. announced their plans to invest in Canada’s first proton therapy treatment centre to be built in Edmonton.
  • The centre will officially be named in honour of Ben Stelter, well-beloved six-year-old superfan and Edmonton Oilers team ambassador whose father, Mike, was a recipient of proton therapy.
  • Proton therapy, a highly precise form of radiation treatment, has long been sought after by Canadians seeking advanced cancer care.
  • On behalf of the EOCF, we would like to congratulate the Ben Stelter Foundation, Edmonton Global and WestCan Proton Therapy for bringing proton therapy treatment to Edmonton.

Global Low Carbon (Green, Blue) Ammonia Industry Research 2024: Focus on United States, Canada, Brazil, Germany, United Kingdom, France, China, Japan, South Korea, and India 2022-2032 - ResearchAndMarkets.com

Retrieved on: 
Tuesday, March 12, 2024
Chemicals, Plastics, Agriculture, Natural Resources, Manufacturing, Carbon, Proton, Growth, Country, Steam, Transport, Porter's five forces analysis, SWOT, ATR, Refrigeration, Carbon footprint, CBAM, European, Hydrogen, SMR, Chemical industry, Alkaline water electrolysis, USD, Fertilizer, Power, Mining

The Global Low Carbon Ammonia market showcased growth at a CAGR of 46.98% during 2022-2025.

Key Points: 
  • The Global Low Carbon Ammonia market showcased growth at a CAGR of 46.98% during 2022-2025.
  • The report analyses the Low Carbon Ammonia Market by Region (Americas, Europe, Asia Pacific, Middle East & Africa) and 10 Countries (United States, Canada, Brazil, Germany, United Kingdom, France, China, Japan, South Korea, and India).
  • Japan and South Korea have set ambitious targets for the use of low carbon hydrogen and ammonia in their national energy strategies.
  • The report analyses the Low Carbon Ammonia Market By End-Use (Industrial Feedstock, Power Generation, Transportation, and Other End-Uses).

Electrolyzers for Green Hydrogen Market Projected to Reach $18.38 billion by 2030 - Exclusive Report by 360iResearch

Retrieved on: 
Thursday, April 4, 2024
Hydrogen, Proton, Cooking, Electricity, Geothermal energy, Growth, KOH, Intelligence, INEOS, Transport, AWE, PEM, Wind, Investment, Oxygen, Chemical industry, S.A, Ammonia, Coal, Table, Fertilizer, Electrolysis

Electrolyzers are at the forefront of the green hydrogen revolution, offering a sustainable method to produce hydrogen by separating water into hydrogen and oxygen using renewable energy sources such as solar and wind power.

Key Points: 
  • Electrolyzers are at the forefront of the green hydrogen revolution, offering a sustainable method to produce hydrogen by separating water into hydrogen and oxygen using renewable energy sources such as solar and wind power.
  • The key players in the Electrolyzers for Green Hydrogen Market include Iberdrola, S.A., INEOS AG, Cummins Inc., LONGi Green Energy Technology Co., Ltd., Siemens AG, and others.
  • We proudly unveil ThinkMi, a cutting-edge AI product designed to transform how businesses interact with the Electrolyzers for Green Hydrogen Market.
  • "Dive into the Electrolyzers for Green Hydrogen Market Landscape: Explore 184 Pages of Insights, 298 Tables, and 22 Figures"

Electrolyzers for Green Hydrogen Market Projected to Reach $18.38 billion by 2030 - Exclusive Report by 360iResearch

Retrieved on: 
Thursday, April 4, 2024
Hydrogen, Proton, Cooking, Electricity, Geothermal energy, Growth, KOH, Intelligence, INEOS, Transport, AWE, PEM, Wind, Investment, Oxygen, Chemical industry, S.A, Ammonia, Coal, Table, Fertilizer, Electrolysis

Electrolyzers are at the forefront of the green hydrogen revolution, offering a sustainable method to produce hydrogen by separating water into hydrogen and oxygen using renewable energy sources such as solar and wind power.

Key Points: 
  • Electrolyzers are at the forefront of the green hydrogen revolution, offering a sustainable method to produce hydrogen by separating water into hydrogen and oxygen using renewable energy sources such as solar and wind power.
  • The key players in the Electrolyzers for Green Hydrogen Market include Iberdrola, S.A., INEOS AG, Cummins Inc., LONGi Green Energy Technology Co., Ltd., Siemens AG, and others.
  • We proudly unveil ThinkMi, a cutting-edge AI product designed to transform how businesses interact with the Electrolyzers for Green Hydrogen Market.
  • "Dive into the Electrolyzers for Green Hydrogen Market Landscape: Explore 184 Pages of Insights, 298 Tables, and 22 Figures"